This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shaw, G. L. Articles by Mulshine, J. L. Search for Related Content PubMed PubMed Citation Articles by Shaw, G. L. Articles by Mulshine, J. L.

Individualized Chemotherapy for Patients with Non-Small Cell Lung Cancer Determined by Prospective Identification of Neuroendocrine Markers and in Vitro Drug Sensitivity Testing

National Cancer Institute, Bethesda, Maryland 20892 [G. L. S., A. F. G., R. P., R. I. L., D. C. I., B. E. J., H. K. O., H. I. P., S. M. S., J. D. M., J. L. M.]; National Naval Medical Center, Bethesda, Maryland 20814 [B. C. G., T. E. W., J. C. N., J. D. C.]; and Uniformed Services University of the Health Sciences, Bethesda, Maryland 20817 [B. C. G., J. D. C.]

We attempted to prospectively select individualized chemotherapy for 165 non-small cell lung cancer patients based on in vitro analysis of neuroendocrine (NE) markers and drug sensitivity testing (DST) using fresh tumor. The chemotherapy used for small cell lung cancer (SCLC) was selected when NE marker expression determined by L-dopa decarboxylase assay was documented. Selection of chemotherapy for other patients was guided by DST results using a modified dye exclusion assay when available; otherwise etoposide and cisplatin was administered. A total of 112 of 165 (68%) specimens were assayed for L-dopa decarboxylase and 36 patients (22%) had DST. In vitro data directed management for 27 of 96 (28%) patients given chemotherapy: 6 with NE markers were treated with the SCLC regimen; and 21 (58% of those with DST) received their DST-selected chemotherapy regimen. There were no significant differences in response rate among all 3 treatment arms (P = 0.076). However, response to chemotherapy for the patients treated prospectively with a SCLC regimen was 3 of 6 (50%), marginally better than patients given their DST-selected chemotherapy regimen (2 of 21; 9%; P = 0.056) or those treated with etoposide and cisplatin (10 of 69; 14%; P = 0.061). When patients whose NE markers were identified retrospectively are included, 4 of 9 (44%) responded to administered chemotherapy, compared to 7 of 55 (13%) with no NE markers present (P = 0.04). There were no differences in survival among the three treatment groups. Cisplatin and etoposide comprised the most active regimen in vitro for tumors from 16 of 36 (44%) patients, potentially limiting the benefit of DST since this is often the empiric therapy for non-SCLC. Furthermore, the correlation between in vitro and clinical response is nonsignificant for all drugs tested, highlighting the overall relative resistance of non-SCLC tumors to currently available chemotherapy.

¹ To whom requests for reprints should be addressed, at Biomarkers and Prevention Research Branch, Division of Cancer Prevention and Control, National Cancer Institute, 9610-C Medical Center Drive, Suite 300, Rockville, Maryland 20850.

² Present address: Simmons Comprehensive Cancer Center, Dallas, TX.

³ Present address: M. D. Anderson Cancer Center, Houston, TX.

Received 6/29/93. Accepted 8/26/93.

This article has been cited by other articles:

				D. J. Samson, J. Seidenfeld, K. Ziegler, and N. Aronson Chemotherapy Sensitivity and Resistance Assays: A Systematic Review J. Clin. Oncol., September 1, 2004; 22(17): 3618 - 3630. [Abstract] [Full Text] [PDF]

				D. Schrag, H. S. Garewal, H. J. Burstein, D. J. Samson, D. D. Von Hoff, and M. R. Somerfield American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays J. Clin. Oncol., September 1, 2004; 22(17): 3631 - 3638. [Abstract] [Full Text] [PDF]

				P. Cortazar and B. E. Johnson Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1625 - 1625. [Abstract] [Full Text] [PDF]

				B. E. JOHNSON, J. P. CHUTE, J. RUSHIN, J. WILLIAMS, P. T. LE, D. VENZON, and G. E. RICHARDSON A Prospective Study of Patients with Lung Cancer and Hyponatremia of Malignancy Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1669 - 1678. [Abstract] [Full Text]